A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation期刊界 All Journals 搜尽天下杂志传播学术成果专业期刊搜索期刊信息化学术搜索

按检索

A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR mutation

Authors:	Youngjoo Lee MD PhD Hye Ryun Kim MD PhD Min Hee Hong MD Ki Hyeong Lee MD PhD Keon Uk Park MD PhD Geon Kook Lee MD PhD Hyae Young Kim MD PhD Soo-Hyun Lee MD Kun Young Lim MD Sung Jin Yoon MS Byoung Chul Cho MD PhD Ji-Youn Han MD PhD

Institution:	1. Center for Lung Cancer, National Cancer Center, Goyang, Republic of Korea;2. Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea;3. Department of Internal Medicine, Chungbuk National University Hospital, Cheongju, Republic of Korea;4. Department of Internal Medicine, Keimyung University Dongsan Hospital, Daegu, Republic of Korea;5. Department of Pathology, National Cancer Center, Goyang, Republic of Korea;6. Department of Radiology, National Cancer Center, Goyang, Republic of Korea

Abstract:

Keywords:	anti-angiogenesis brain metastasis EGFR mutation nonsmall cell lung cancer targeted therapy